{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:07:47Z","timestamp":1782281267204,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00467-024-06531-1","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:16:42Z","timestamp":1730110602000},"page":"797-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-3022","authenticated-orcid":false,"given":"Eva","family":"Degraeuwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Gasthuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Snauwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Dossche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Prytula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Dehoorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Vande","family":"Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"6531_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","volume":"390","author":"E Gakidou","year":"2017","unstructured":"Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM et al (2017) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1345\u20131422","journal-title":"Lancet"},{"key":"6531_CR2","doi-asserted-by":"crossref","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al (2015) Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circ 131:e29\u2013322","DOI":"10.1161\/CIR.0000000000000152"},{"key":"6531_CR3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00467-019-04314-7","volume":"35","author":"N Siddiqi","year":"2020","unstructured":"Siddiqi N, Shatat IF (2020) Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol 35:2049\u20132065","journal-title":"Pediatr Nephrol"},{"key":"6531_CR4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.113.3.475","volume":"113","author":"JM Sorof","year":"2004","unstructured":"Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ (2004) Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113:475\u2013482","journal-title":"Pediatrics"},{"key":"6531_CR5","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00467-008-0744-y","volume":"24","author":"MM Grinsell","year":"2009","unstructured":"Grinsell MM, Norwood VF (2009) At the bottom of the differential diagnosis list: Unusual causes of pediatric hypertension. Pediatr Nephrol 24:2137\u20132146","journal-title":"Pediatr Nephrol"},{"key":"6531_CR6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40885-020-00156-w","volume":"26","author":"M Ashraf","year":"2020","unstructured":"Ashraf M, Irshad M, Parry NA (2020) Pediatric hypertension: an updated review. Clin Hypertens 26:22","journal-title":"Clin Hypertens"},{"key":"6531_CR7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00467-008-1077-6","volume":"24","author":"R Lubrano","year":"2009","unstructured":"Lubrano R, Travasso E, Raggi C, Guido G, Masciangelo R, Elli M (2009) Blood pressure load, proteinuria and renal function in pre-hypertensive children. Pediatr Nephrol 24:823\u2013831","journal-title":"Pediatr Nephrol"},{"key":"6531_CR8","doi-asserted-by":"crossref","first-page":"785356","DOI":"10.3389\/fped.2021.785356","volume":"9","author":"T Azegami","year":"2021","unstructured":"Azegami T, Uchida K, Tokumura M, Mori M (2021) Blood pressure tracking from childhood to adulthood. Front Pediatr 9:785356","journal-title":"Front Pediatr"},{"key":"6531_CR9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2007.09.019","volume":"29","author":"MR Weir","year":"2007","unstructured":"Weir MR (2007) Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 29:1803\u20131824","journal-title":"Clin Ther"},{"key":"6531_CR10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1542\/pir.2018-0014","volume":"40","author":"DJ Weaver","year":"2019","unstructured":"Weaver DJ (2019) Pediatric hypertension: review of updated guidelines. Pediatrics Rev 40:354\u2013358","journal-title":"Pediatrics Rev"},{"key":"6531_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.S2.555","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","unstructured":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555\u2013576","journal-title":"Pediatrics"},{"key":"6531_CR12","first-page":"201","volume":"29","author":"S Yagi","year":"2013","unstructured":"Yagi S, Akaike M, Aihara KI, Fukuda D, Ishida M, Ise T et al (2013) Pharmacology of aldosterone and the effects of mineralocorticoid receptor blockade on cardiovascular systems. Acta Cardiol Sin 29:201","journal-title":"Acta Cardiol Sin"},{"key":"6531_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E W\u00fchl","year":"2009","unstructured":"ESCAPE Trial Group, W\u00fchl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, M\u00f6ller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639\u20131650. https:\/\/doi.org\/10.1056\/NEJMoa0902066","journal-title":"N Engl J Med"},{"key":"6531_CR14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11906-012-0245-z","volume":"14","author":"T Thethi","year":"2012","unstructured":"Thethi T, Kamiyama M, Kobori H (2012) The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 14:160","journal-title":"Curr Hypertens Rep"},{"key":"6531_CR15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF00196112","volume":"46","author":"M Neubeck","year":"1994","unstructured":"Neubeck M, Fliser D, Pritsch M, Wei\u00dfer K, Fliser M, Nussberger J et al (1994) Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure - consequence of dose adjustment. Eur J Clin Pharmacol 46:537\u2013543","journal-title":"Eur J Clin Pharmacol"},{"key":"6531_CR16","unstructured":"Hidayani T (2019) Blood pressure levels for boys by age and height percentile. https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/child_tbl.pdf. Accessed 26 Jun 2024"},{"key":"6531_CR17","unstructured":"Roelants M, Hauspie R, Hebbelinck M, Brusselaers K (2009) [Flemish growth curves 2004]. https:\/\/researchportal.vub.be\/nl\/publications\/vlaamse-groeicurven-2004. Accessed 17 Apr 2024"},{"key":"6531_CR18","unstructured":"European Medicines Agency (n.d.) Needs for paediatric medicines. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/paediatric-medicines-research-and-development\/needs-paediatric-medicines. Accessed 26 Jun 2024"},{"key":"6531_CR19","unstructured":"U.S. Food and Drug Administration (2020) New Pediatric Labeling Information Database - Detail. https:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdDetailNavigation.cfm?sd=labelingdatabase&id=14. Accessed 11 Apr 2023"},{"key":"6531_CR20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"6531_CR21","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.3390\/ijerph19105960","volume":"19","author":"A Deja","year":"2022","unstructured":"Deja A, Skrzypczyk P, Nowak M, Wro\u0144ska M, Szyszka M, Ofiara A et al (2022) Evaluation of active renin concentration in a cohort of adolescents with primary hypertension. Int J Environ Res Public Health 19:5960","journal-title":"Int J Environ Res Public Health"},{"key":"6531_CR22","volume-title":"Pediatric hypertension","year":"2023","unstructured":"Flynn JT, Ingelfinger JR, Brady TM (eds) (2023) Pediatric hypertension, 5th edn. Springer, Cham","edition":"5"},{"key":"6531_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2007.004","volume":"8","author":"A Raes","year":"2007","unstructured":"Raes A, Malfait F, Van Aken S, France A, Donckerwolcke R, VandeWalle J (2007) Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. J Renin Angiotensin Aldosterone Syst 8:3\u201312","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"6531_CR24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0895-7061(03)00900-2","volume":"16","author":"B Soffer","year":"2003","unstructured":"Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S (2003) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 16:795\u2013800","journal-title":"Am J Hypertens"},{"key":"6531_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.127","volume":"98","author":"H Trachtman","year":"2015","unstructured":"Trachtman H, Frymoyer A, Lewandowski A, Greenbaum LA, Feig DI, Gipson DS et al (2015) Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: implications for starting dose selection. Clin Pharmacol Ther 98:25\u201333","journal-title":"Clin Pharmacol Ther"},{"key":"6531_CR26","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904","journal-title":"Pediatrics"},{"key":"6531_CR27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/HJH.0000000000001039","volume":"34","author":"E Lurbe","year":"2016","unstructured":"Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A et al (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887\u20131920","journal-title":"J Hypertens"},{"key":"6531_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/HYPERTENSIONAHA.118.11819","volume":"73","author":"MB Lande","year":"2019","unstructured":"Lande MB, Batisky DL (2019) New American Academy of Pediatrics hypertension guideline. Hypertension 73:31\u201332","journal-title":"Hypertension"},{"key":"6531_CR29","first-page":"86","volume":"8","author":"RR Carr","year":"2003","unstructured":"Carr RR, Ensom MHH (2003) Drug disposition and therapy in adolescence: the effects of puberty. J Pediatr Pharmacol Ther 8:86\u201396","journal-title":"J Pediatr Pharmacol Ther"},{"key":"6531_CR30","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/HJH.0b013e32832f4f6b","volume":"27","author":"E Lurbe","year":"2009","unstructured":"Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C et al (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719\u20131742","journal-title":"J Hypertens"},{"key":"6531_CR31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-005-1855-3","volume":"20","author":"JT Flynn","year":"2005","unstructured":"Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol 20:961\u2013966","journal-title":"Pediatr Nephrol"},{"key":"6531_CR32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF00735961","volume":"18","author":"RT Gansevoort","year":"1996","unstructured":"Gansevoort RT, De Zeeuw D, De Jong PE (1996) ACE inhibitors and proteinuria. Pharm World Sci 18:204\u2013210","journal-title":"Pharm World Sci"},{"key":"6531_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117\u2013124","journal-title":"Lancet"},{"key":"6531_CR34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12882-017-0789-x","volume":"18","author":"CM Gant","year":"2017","unstructured":"Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F et al (2017) Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol 18:370","journal-title":"BMC Nephrol"},{"key":"6531_CR35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-3476(76)80460-X","volume":"89","author":"HP Stalker","year":"1976","unstructured":"Stalker HP, Holland NH, Kotchen JM, Kotchen TA (1976) Plasma renin activity in healthy children. J Pediatr 89:256\u2013258","journal-title":"J Pediatr"},{"key":"6531_CR36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","volume":"77","author":"N Yozamp","year":"2021","unstructured":"Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B et al (2021) Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension 77:891\u2013899","journal-title":"Hypertension"},{"key":"6531_CR37","first-page":"13","volume":"2014","author":"M Pacurari","year":"2014","unstructured":"Pacurari M, Kafoury R, Tchounwou PB, Ndebele K (2014) The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014:13","journal-title":"Int J Inflam"},{"key":"6531_CR38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3:486\u2013492","journal-title":"Nat Clin Pract Nephrol"},{"key":"6531_CR39","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/HJH.0b013e32834c625c","volume":"29","author":"F Schaefer","year":"2011","unstructured":"Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A et al (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 29:2484\u20132490","journal-title":"J Hypertens"},{"key":"6531_CR40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13063-024-08021-z","volume":"25","author":"F Schaefer","year":"2024","unstructured":"Schaefer F, Montini G, Kang HG, VandeWalle J, Zaritsky J, Schreuder MF et al (2024) Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials 25:203","journal-title":"Trials"},{"key":"6531_CR41","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","volume":"61","author":"DA Smith","year":"2018","unstructured":"Smith DA, Beaumont K, Maurer TS, Di L (2018) Relevance of half-life in drug design. J Med Chem 61:4273\u20134282","journal-title":"J Med Chem"},{"key":"6531_CR42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2510100407","volume":"10","author":"B Beermann","year":"1989","unstructured":"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren IL (1989) Pharmacokinetics of lisinopril (IV\/PO) in healthy volunteers. Biopharm Drug Dispos 10:397\u2013409","journal-title":"Biopharm Drug Dispos"},{"key":"6531_CR43","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jch.13011","volume":"19","author":"T Tsai","year":"2017","unstructured":"Tsai T, Kroehl ME, Smith SM, Thompson AM, Dai IY, Trinkley KE (2017) Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. J Clin Hypertens 19:868","journal-title":"J Clin Hypertens"},{"key":"6531_CR44","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3109\/07420528.2010.510230","volume":"27","author":"RC Hermida","year":"2010","unstructured":"Hermida RC, Ayala DE, Moj\u00f3n A, Fern\u00e1ndez JR (2010) Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 27:1629\u20131651","journal-title":"Chronobiol Int"},{"key":"6531_CR45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/07420528.2012.709448","volume":"30","author":"RC Hermida","year":"2013","unstructured":"Hermida RC, Ayala DE, Fern\u00e1ndez JR et al (2013) Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 30:280\u2013314","journal-title":"Chronobiol Int"},{"key":"6531_CR46","first-page":"7428439","volume":"10","author":"Z Fu","year":"2021","unstructured":"Fu Z, Geng X, Chi K, Song C, Wu D, Liu C et al (2021) Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med 10:7428439\u20137427439","journal-title":"Ann Palliat Med"},{"key":"6531_CR47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semnephrol.2021.09.003","volume":"41","author":"I Sandokji","year":"2021","unstructured":"Sandokji I, Greenberg JH (2021) Plasma and urine biomarkers of CKD: a review of findings in the CKiD study. Semin Nephrol 41:416\u2013426","journal-title":"Semin Nephrol"},{"key":"6531_CR48","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/HYPERTENSIONAHA.122.19312","volume":"79","author":"AM Ateya","year":"2022","unstructured":"Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA (2022) Effects of ramipril on biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis: the SEARCH randomized placebo-controlled trial. Hypertension 79:1856\u20131865","journal-title":"Hypertension"},{"key":"6531_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-01312-3","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu Y, Lin Y, Zhang MM, Li XH, Liu YY, Zhao J et al (2020) The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension. BMC Cardiovasc Disord 20:1\u20137","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06531-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:21:57Z","timestamp":1737368517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06531-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6531"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06531-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and approved by the ethical committee of Ghent University Hospital (BC 09909) on the 14th of July 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical committee"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}